Literature DB >> 23104175

Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion.

Xiao-Xing Kou1, Ting Hao, Zhen Meng, Yan-Heng Zhou, Ye-Hua Gan.   

Abstract

Specificity protein 1 (Sp1) is often overexpressed in cancer cells. Its binding sites are known to exist in the phosphatase and tension homolog deleted on chromosome 10 (PTEN) promoter. In this study, we hypothesized that Sp1 negatively regulates PTEN expression. We used several cell lines to determine the effects of Sp1. The results showed that Sp1 overexpression inhibited the expression and promoter activity of PTEN and correspondingly upregulated AKT phosphorylation, whereas Sp1 knockdown upregulated the expression and promoter ability of PTEN and downregulated AKT phosphorylation. Moreover, a series of deletion and site-directed mutations of the PTEN promoter indicated that Sp1 can inhibit PTEN promoter activity through a specific Sp1-binding site at the PTEN core promoter in vivo. Meanwhile, non-acetylated Sp1, with its loss of DNA binding activity, failed to inhibit the expression and promoter activity of PTEN. Histone deacetylase 1 was necessary for Sp1 to inhibit PTEN expression. The inverse expression of Sp1 and PTEN was found in tongue cancer cells and salivary adenoid cystic cancer (SACC)-LM cells (possessing higher potential for lung metastasis than SACC-83) as compared with that in adjacent normal tissue and SACC-83 cells, respectively. Sp1 knockdown decreased the migration and invasion of SACC-LM cells, whereas Sp1 overexpression increased the migration and invasion of SACC-83 cells. Overall, these results suggest that Sp1 is involved in the development and invasiveness of cancer through inhibition of PTEN.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104175     DOI: 10.1093/carcin/bgs336

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  22 in total

1.  PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.

Authors:  Z Meng; L-F Jia; Y-H Gan
Journal:  Oncogene       Date:  2015-08-17       Impact factor: 9.867

2.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

3.  Elevated histone H3 acetylation and loss of the Sp1-HDAC1 complex de-repress the GM2-synthase gene in renal cell carcinoma.

Authors:  Avisek Banerjee; Barun Mahata; Arjun Dhir; Tapan Kumar Mandal; Kaushik Biswas
Journal:  J Biol Chem       Date:  2018-11-21       Impact factor: 5.157

4.  ΔNp63α promotes the expression and nuclear translocation of PTEN, leading to cisplatin resistance in oral cancer cells.

Authors:  Ting Hao; Ye-Hua Gan
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 5.  microRNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in Preclinical In Vivo Models.

Authors:  Ulrich H Weidle; Ulrich Brinkmann; Simon Auslaender
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

6.  LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway.

Authors:  Hongzao Ni; Kai Wang; Peng Xie; Jiandong Zuo; Wenguang Liu; Chun Liu
Journal:  Cell Mol Neurobiol       Date:  2020-03-31       Impact factor: 5.046

7.  DNA demethylation in the PTEN gene promoter induced by 5-azacytidine activates PTEN expression in the MG-63 human osteosarcoma cell line.

Authors:  Deye Song; Jiangdong Ni; Hongming Xie; Muliang Ding; Jun Wang
Journal:  Exp Ther Med       Date:  2014-02-21       Impact factor: 2.447

8.  Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway.

Authors:  Qingling Li; Jie Li; Ting Wen; Weiqi Zeng; Cong Peng; Siyu Yan; Jieqiong Tan; Keda Yang; Shuang Liu; Aiyuan Guo; Chong Zhang; Juan Su; Minghao Jiang; Zhaoqian Liu; Honghao Zhou; Xiang Chen
Journal:  Oncotarget       Date:  2014-08-15

9.  HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells.

Authors:  Dong-Qin Chen; Ban-Zhou Pan; Jia-Yuan Huang; Kai Zhang; Shi-Yun Cui; Wei De; Rui Wang; Long-Bang Chen
Journal:  Oncotarget       Date:  2014-05-30

10.  Sp1-mediated ectopic expression of T-cell lymphoma invasion and metastasis 2 in hepatocellular carcinoma.

Authors:  Wei-Hsuan Yen; Wu-Sian Ke; Jan-Jong Hung; Tsung-Ming Chen; Jia-Shing Chen; H S Sun
Journal:  Cancer Med       Date:  2016-01-14       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.